文献速递肾小球疾病慢性肾脏病

Testican-2与细胞外基质相互作用及足细胞保护

Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection.
PubMed 文献 · J Am Soc Nephrol · 2025-10-28

本研究探讨足细胞来源糖蛋白Testican-2的生物学功能。体外和动物实验显示Testican-2可减轻阿霉素诱导的足细胞损伤,其机制为结合玻连蛋白并抑制整合素αVβ3激活;在Spock2敲除小鼠中,外源性Testican-2仍能循环至肾脏发挥保护作用。人肾活检显示FSGS和糖尿病肾病中肾小球Testican-2表达降低。

要点

  • Testican-2结合玻连蛋白,抑制整合素αVβ3激活,减轻足细胞损伤。
  • 外源性Testican-2可循环至肾脏,在Spock2缺失时仍保护足细胞。
  • FSGS和糖尿病肾病患者肾小球Testican-2表达降低。

核心结论

  • Testican-2通过结合玻连蛋白、抑制整合素αVβ3激活来减轻足细胞损伤,发挥肾脏保护功能。

研究设计与样本

  • 研究使用永生化培养的人足细胞和经阿霉素处理的小鼠,以及全局和足细胞特异性Spock2敲除小鼠模型,并用免疫共沉淀质谱和生物层干涉术鉴定结合伙伴,最后分析人肾活检样本中Testican-2表达。

主要发现

  • Testican-2在体外和体内均减轻阿霉素诱导的足细胞损伤。
  • 玻连蛋白是Testican-2的强结合伙伴,Testican-2抑制玻连蛋白与整合素αVβ3的相互作用。
  • Spock2缺失增加阿霉素和链脲佐菌素诱导糖尿病所致的足细胞损伤易感性,表现为白蛋白尿、足突消失、nephrin表达和Wilms肿瘤1阳性足细胞数量改变。
  • 外源性Testican-2循环至肾脏,结合玻连蛋白,减少玻连蛋白-整合素β3相互作用,并减轻Spock2缺陷小鼠的足细胞损伤。
  • 人局灶节段性肾小球硬化和糖尿病肾病中肾小球Testican-2表达降低,但肾小管间质肾病中未降低。

临床怎么用

  • Testican-2可能作为足细胞保护的治疗靶点,外源性给药在Spock2缺失时仍有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. BACKGROUND: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. METHODS: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein-protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2-deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. RESULTS: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. CONCLUSIONS: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wen D, Zhang Q, van Agthoven J, et al. Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection. J Am Soc Nephrol. 2025. PMID: 41177530. doi:10.1681/ASN.0000000915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。